Hikma Pharmaceuticals (LSE:HIK) Land And Improvements : £630 Mil (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Hikma Pharmaceuticals Land And Improvements?

Hikma Pharmaceuticals's land and improvements for the quarter that ended in Dec. 2023 was £630 Mil.

Hikma Pharmaceuticals's quarterly land and improvements declined from Dec. 2022 (£595 Mil) to Jun. 2023 (£0 Mil) but then increased from Jun. 2023 (£0 Mil) to Dec. 2023 (£630 Mil).

Hikma Pharmaceuticals's annual land and improvements increased from Dec. 2021 (£508 Mil) to Dec. 2022 (£595 Mil) and increased from Dec. 2022 (£595 Mil) to Dec. 2023 (£630 Mil).

Hikma Pharmaceuticals Land And Improvements Historical Data

The historical data trend for Hikma Pharmaceuticals's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikma Pharmaceuticals Land And Improvements Chart

Hikma Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Land And Improvements

Get a 7-Day Free Trial

455.51

473.18

508.35

595.23

629.63

Hikma Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Land And Improvements	Get a 7-Day Free Trial															508.35	-	595.23	-	629.63

Hikma Pharmaceuticals Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Hikma Pharmaceuticals (LSE:HIK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (LSE:HIK) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

HKMPY:USA HKMPF:USA HIKl:UK H5P:Germany

Address

1 New Burlington Place, London, GBR, W1S 2HR

Website

https://www.hikma.com

Hikma Pharmaceuticals PLC is engaged in the development, manufacture, and marketing of a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the company's sales are based in the U.S. and to a lesser degree in the Middle East, North Africa, and Europe.

Hikma Pharmaceuticals (LSE:HIK) Headlines

No Headlines